Bone-targeted therapy for metastatic breast cancer—Where do we go from here? A commentary from the BONUS 8 meeting

by Xiaofu Zhu, Eitan Amir, Gurmit Singh, Mark Clemons, Christina Addison
Published 2014-03-01

Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting

by Carmel Jacobs, Eitan Amir, Alexander Paterson, Xiaofu Zhu, Mark Clemons
Published 2015-06-01

Suivre des voies parallèles : perspectives de patientes et de médecins sur les raisons pour lesquelles les femmes tardent à rechercher des soins pour leurs symptômes de cancer du s...

by Leeat Granek, Barbara Fitzgerald, Karen Fergus, Mark Clemons, Ruth Heisey
Published 2012-04-01

Travelling on parallel tracks: Patient and physician perspectives on why women delay seeking care for breast cancer symptoms

by Leeat Granek, Barbara Fitzgerald, Karen Fergus, Mark Clemons, Ruth Heisey
Published 2012-04-01

Pourquoi les femmes diffèrent-elles leur recours aux soins relativement à un cancer du sein localement avancé

by Judy Gould, Barbara Fitzgerald, Karen Fergus, Mark Clemons, Fauzia Baig
Published 2010-01-01

Why women delay seeking assistance for locally advanced breast cancer

by Judy Gould, Barbara Fitzgerald, Karen Fergus, Mark Clemons, Fauzia Baig
Published 2010-01-01

Renal cell carcinoma bone metastases: clinical advances

by Chakshu Sahi, Jennifer J. Knox, Mark Clemons, Anthony M. Joshua, Reuben Broom
Published 2010-03-01

Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases

by Demetrios Simos, Christina L. Addison, Iryna Kuchuk, Brian Hutton, Sasha Mazzarello, Mark Clemons
Published 2013-08-01

Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial).

by John Hilton, Carol Stober, Sasha Mazzarello, Lisa Vandermeer, Dean Fergusson, Brian Hutton, Mark Clemons
Published 2018-01-01

Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.

by Carmel Jacobs, Ian D Graham, Julie Makarski, Michaël Chassé, Dean Fergusson, Brian Hutton, Mark Clemons
Published 2014-01-01

Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic

by Tabitha Tse, Sandeep Sehdev, Jean Seely, Denis H. Gravel, Mark Clemons, Erin Cordeiro, Angel Arnaout
Published 2021-03-01

Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG...

by Christina L. Addison, Gregory R. Pond, Brandy Cochrane, Huijun Zhao, Stephen K. Chia, Mark N. Levine, Mark Clemons
Published 2015-06-01

Evaluating the Feasibility of Performing Window of Opportunity Trials in Breast Cancer

by Angel Arnaout, Susan Robertson, Iryna Kuchuk, Demetrios Simos, Gregory R. Pond, Christina L. Addison, Mehrzad Namazi, Mark Clemons
Published 2015-01-01

Benefits and harms of medical cannabis: a scoping review of systematic reviews

by Misty Pratt, Adrienne Stevens, Micere Thuku, Claire Butler, Becky Skidmore, L. Susan Wieland, Mark Clemons, Salmaan Kanji, Brian Hutton
Published 2019-12-01

Does the Time of Day at Which Endocrine Therapy Is Taken Affect Breast Cancer Patient Outcomes?

by Ana-Alicia Beltran-Bless, Lisa Vandermeer, Mohammed F. K. Ibrahim, Brian Hutton, Risa Shorr, Marie-France Savard, Mark Clemons
Published 2021-07-01

Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey

by Mashari AlZahrani, Mark Clemons, Lisa Vandermeer, Marta Sienkiewicz, Arif Ali Awan, Brian Hutton, Gregory R. Pond, Terry L. Ng
Published 2021-02-01

Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review

by Ricardo Fernandes, Sasha Mazzarello, Carol Stober, Mohamed F.K. Ibrahim, Shaan Dudani, Kirstin Perdrizet, Habeeb Majeed, Lisa Vandermeer, Risa Shorr, Brian Hutton, Dean Fergusson, Bishal Gyawali, Mark Clemons
Published 2017-04-01

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer

by Megan M. Tu, Mark Clemons, Carol Stober, Ahwon Jeong, Lisa Vandermeer, Mihaela Mates, Phillip Blanchette, Anil Abraham Joy, Olexiy Aseyev, Gregory Pond, Dean Fergusson, Terry L. Ng, Kednapa Thavorn
Published 2021-05-01

Future directions for bone metastasis research – highlights from the 2015 bone and the Oncologist new updates conference (BONUS)

by Ricardo Fernandes, Peter Siegel, Svetlana Komarova, John Hilton, Christina Addison, Mohammed F K Ibrahim, Joel Werier, Kristopher Dennis, Gurmit Singh, Eitan Amir, Virginia Jarvis, Urban Emmenegger, Sasha Mazzarello, Mark Clemons
Published 2016-06-01

Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation

by Sharon McGee, Mashari AlZahrani, Carol Stober, Terry L. Ng, Katherine Cole, Gail Larocque, Arif Awan, Sandeep Sehdev, John Hilton, Lisa Vandermeer, Brian Hutton, Gregory Pond, Deanna Saunders, Mark Clemons
Published 2021-04-01